Clinical Trials Arena17h
Asceletis’ muscle-preserving weight loss therapy sustains 40-day half-life
The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.
News-Medical.Net22h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025ORKA-001 Phase 2a initiation expected in ...